Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic, Amgen Ink Deal to Develop Test for KRAS, NRAS

NEW YORK (GenomeWeb News) – Transgenomic today announced a deal with Amgen to develop a CE-IVD test to screen patients with metastatic colorectal cancer for KRAS and NRAS mutations.

The mutations will be identified with Transgenomic's CE-IVD CRC RAScan kits, which use Surveyor-Wave technology. The test will allow physicians to incorporate tumor mutation status into their treatment decisions.

The Omaha, Neb.-based company said its CLIA laboratory is available to immediately receive patient samples for testing. The CE-IVD test kits will be available in Europe, as well as in the US soon as research use only products.

Financial and other terms of the alliance were not disclosed.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.